JAHA:患者的教育程度与药物依从性呈相关性

2019-05-31 不详 MedSci原创

急性冠脉综合征后的药物治疗依从性较差,尤其在边缘化的患者人群中。患者的教育程度可能提高药物的依从性,但这种相关性尚不确定,尤其是边缘化人群。本研究纳入了国家数据库中的出院诊断是冠脉综合征的患者(n=33199),然后,评估了出院后6个月内的患者教育接触人数,以及最多5年内预防性药物的开始和停用情况。经并发症和人口统计学参数调整后,发现接触有3个或3个以上教育程度高的患者使用预防性药物的概率更高,相

急性冠脉综合征后的药物治疗依从性较差,尤其在边缘化的患者人群中。患者的教育程度可能提高药物的依从性,但这种相关性尚不确定,尤其是边缘化人群。

本研究纳入了国家数据库中的出院诊断是冠脉综合征的患者(n=33199),然后,评估了出院后6个月内的患者教育接触人数,以及最多5年内预防性药物的开始和停用情况。经并发症和人口统计学参数调整后,发现接触有3个或3个以上教育程度高的患者使用预防性药物的概率更高,相对应的风险从他汀类药物的1.12 (95% CI, 1.06-1.18)到ADP抑制剂的1.39 (95% CI, 1.28-1.51)。另外,这类患者的后续药物依从性也更高,药物的中断风险从他汀类药物的0.86 (95% CI, 0.79-0.92)到β受体阻滞剂的0.92 (95% CI, 0.88-0.97)。

研究结果显示,对于急性冠脉综合征患者,高的教育程度可以提高患者药物的使用率和依从性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649368, encodeId=d0871649368f2, content=<a href='/topic/show?id=8de85e61308' target=_blank style='color:#2F92EE;'>#教育程度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57613, encryptionId=8de85e61308, topicName=教育程度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2023807279, createdName=qingting, createdTime=Fri Jun 14 16:21:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032300, encodeId=065e203230076, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Sep 18 04:21:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837690, encodeId=51d3183e6902c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 31 05:21:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268155, encodeId=6c771268155be, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319341, encodeId=387b131934178, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649368, encodeId=d0871649368f2, content=<a href='/topic/show?id=8de85e61308' target=_blank style='color:#2F92EE;'>#教育程度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57613, encryptionId=8de85e61308, topicName=教育程度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2023807279, createdName=qingting, createdTime=Fri Jun 14 16:21:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032300, encodeId=065e203230076, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Sep 18 04:21:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837690, encodeId=51d3183e6902c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 31 05:21:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268155, encodeId=6c771268155be, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319341, encodeId=387b131934178, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649368, encodeId=d0871649368f2, content=<a href='/topic/show?id=8de85e61308' target=_blank style='color:#2F92EE;'>#教育程度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57613, encryptionId=8de85e61308, topicName=教育程度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2023807279, createdName=qingting, createdTime=Fri Jun 14 16:21:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032300, encodeId=065e203230076, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Sep 18 04:21:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837690, encodeId=51d3183e6902c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 31 05:21:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268155, encodeId=6c771268155be, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319341, encodeId=387b131934178, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649368, encodeId=d0871649368f2, content=<a href='/topic/show?id=8de85e61308' target=_blank style='color:#2F92EE;'>#教育程度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57613, encryptionId=8de85e61308, topicName=教育程度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2023807279, createdName=qingting, createdTime=Fri Jun 14 16:21:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032300, encodeId=065e203230076, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Sep 18 04:21:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837690, encodeId=51d3183e6902c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 31 05:21:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268155, encodeId=6c771268155be, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319341, encodeId=387b131934178, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
    2019-06-02 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1649368, encodeId=d0871649368f2, content=<a href='/topic/show?id=8de85e61308' target=_blank style='color:#2F92EE;'>#教育程度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57613, encryptionId=8de85e61308, topicName=教育程度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2023807279, createdName=qingting, createdTime=Fri Jun 14 16:21:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032300, encodeId=065e203230076, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Sep 18 04:21:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837690, encodeId=51d3183e6902c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Aug 31 05:21:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268155, encodeId=6c771268155be, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319341, encodeId=387b131934178, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jun 02 00:21:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
    2019-06-02 fyxzlh

相关资讯

JACC:过高的肺动脉高压诊断标准与死亡率增高相关

越来越多的证据表明现有的肺动脉高压(PHT)诊断标准低估了PHT的预后影响。本研究的目的旨在一个澳大利亚人群队列中评估升高的PHT对预后的影响。本研究对157842名研究对象进行了右室收缩压(eRVSP)的检测,并随访其远期预后。该队列包含74405名男性和83437名女性,平均年龄为65.6±17.7岁,最终,根据eRVSP,有17955名(11.4%)、7016名(4.4%)和4515名(2.

OCC 2019:心血管指南丨大咖陪你一起读

2019OCC精彩内容,让你一次看个够!

OCC 2019:李勇|2018中国高血压防治指南

在经历2017ACC及2018ESC高血压指南的巨大更新后,我们国家自己的《中国高血压防治指南2018年修订版》也终于在不断地争议后出版了。李教授指出,新版指南不仅更新了我国高血压流行病学新数据,更新了高血压患者的降压目标,修改了降压药的应用基本原则、联合用药的适应证,并对特殊人群高血压的处理进行了更新。我国人群高血压流行情况高血压与心血管风险诊断性评估内容包括以下三方面:各种血压测量方法评价评估

Lancet力挺阿司匹林:二级预防不增加出血风险!JAMA子刊:生活目标积极的人更长寿

早晨起来,拥抱太阳,让身体充满,灿烂的阳光,满满的正能量!

JACC:雷帕霉素可减少心脏移植术后肿瘤发生率

恶性肿瘤是心脏移植后的主要死亡原因,雷帕霉素(SRL)作为抗增殖药物是心脏移植后需长期服用的药物,可能降低患者的死亡率。本研究的目的旨在评估基于钙调神经磷酸酶抑制剂(CNI)的免疫抑制(IS)转变为基于SRL的IS是否能降低心脏移植后的恶性肿瘤发生率。本研究纳入了1994-2016接受有心脏移植的523名患者,主要终点事件包括新发恶性肿瘤的发生、移植后淋巴增生性疾病(PTLD)。最终,共有307名

JAHA:能量饮料可影响健康人群的心电图参数和血压

能量饮料可增加急诊的发病率和死亡率,本研究的目的旨在评估能量饮料对健康年轻人的心电图参数和血压的影响。本次随机双盲对照试验纳入了34名健康参与者(平均年龄22.1±3.0岁),参与者随机分成能量饮料A组、能量饮料B组和安慰剂组。主要终点事件是QTc间期,次要终点事件是QT间期、PR间期、QRS持续时间、心率和血压。能量饮料干预与时间的交互作用与校正后的QT间期明显相关,与PR间期、QRS持续时间、